The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML).
Department of Medicine and Oncology, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, H3T 1E2, Canada. Sarit.Assouline@mcgill.ca.
Acute myeloid leukemia (AML) is nearly always a fatal malignancy. For the past 40 years, the standard of care remains a combination of cytarabine and an anthracycline known as 7 + 3. This treatment regimen is troubled by both low survival rates (10% at 5 years) and deaths due to toxicity. Substantial new laboratory findings over the past decade have identified many cellular pathways that contribute to leukemogenesis. These studies have led to the development of novel agents designed to target these pathways. Here we discuss the molecular underpinnings and clinical benefits of these novel treatment strategies. Most importantly these studies demonstrate that clinical response is best achieved by stratifying each patient based on a detailed understanding of their molecular abnormalities.
Cancers (Basel) 2012;4(4):1161-79.
Pubmed ID: 24213503